Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

13:53 MIN

CIDP
GBS
MMN

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

DOWNLOAD PDF

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Claudia Sommer, MD

University of Würzburg, Würzburg, Germany

9:35 MIN

CIDP
MMN

Discover the results of two recent clinical studies of IVIg treatments for CIDP.

DOWNLOAD PDF

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

14:01 MIN

CIDP

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

DOWNLOAD PDF

Wear-Off in IVIG and What it Means in Clinical Practice

Jeffrey A. Allen, MD
Carol L. Koski, MD
Thomas Harbo, MD

16:21 MIN

CIDP

Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.

SELECT A CHAPTER TO VIEW

Introduction

Introduction to wear-off effects

Monitoring wear-off effects

Combating wear-off effects

Conclusion

NOW PLAYING

13:53

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

NOW PLAYING

9:35

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Discover the results of two recent clinical studies of IVIg treatments for CIDP.

NOW PLAYING

14:01

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

NOW PLAYING

16:21

Wear-Off in IVIG and What it Means in Clinical Practice

Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.

Our Experts on CIDP

VIEW ALL EXPERTS

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

CIDP

Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

CIDP
GBS
MMN

Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.

Jeffrey A. Allen, MD

University of Minnesota